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Background. Lymphoma incidence is increased among human immunodeficiency virus (HIV)–infected indi-
viduals soon after antiretroviral therapy (ART), perhaps due to unmasking immune reconstitution inflammatory
syndrome (IRIS). Clinical characteristics and survival for unmasking lymphoma IRIS have not been described.
Methods. We studied lymphoma patients in the Centers for AIDS Research Network of Integrated Clinical Sys-
tems (CNICS) from 1996 until 2011. Unmasking lymphoma IRIS was defined as lymphoma within 6 months after
ART accompanied by a ≥0.5 log10 copies/mL HIV RNA reduction. Differences in presentation and survival were
examined between IRIS and non-IRIS cases.
Results. Of 482 lymphoma patients, 56 (12%) met criteria for unmasking lymphoma IRIS. Of these, 12 (21%)
had Hodgkin lymphoma, 22 (39%) diffuse large B-cell lymphoma, 5 (9%) Burkitt lymphoma, 10 (18%) primary
central nervous system lymphoma, and 7 (13%) other non-Hodgkin lymphoma. Median CD4 cell count at lympho-
ma diagnosis among IRIS cases was 173 cells/µL (interquartile range, 73–302), and 48% had suppressed HIV RNA
<400 copies/mL. IRIS cases were similar overall to non-IRIS cases in histologic distribution and clinical character-
istics, excepting more frequent hepatitis B and C (30% vs 19%, P = .05), and lower HIV RNA at lymphoma diagnosis
resulting from the IRIS case definition. Overall survival at 5 years was similar between IRIS (49%; 95% confidence
interval [CI], 37%–64%) and non-IRIS (44%; 95% CI, 39%–50%), although increased early mortality was suggested
among IRIS cases.
Conclusions. In a large HIV-associated lymphoma cohort, 12% of patients met a uniformly applied unmasking
lymphoma IRIS case definition. Detailed studies of lymphoma IRIS might identify immunologic mechanisms of
lymphoma control.
Keywords. HIV/AIDS; lymphoma; Hodgkin lymphoma; non-Hodgkin lymphoma; immune reconstitution
inflammatory syndrome.
Individuals infected with human immunodeficiency
virus (HIV) have increased incidence of non-Hodgkin
lymphoma (NHL) and Hodgkin lymphoma (HL) dur-
ing the first 6 months after antiretroviral therapy (ART)
[1–3]. This may be due to immune reconstitution in-
flammatory syndrome (IRIS). IRIS is well described
for opportunistic infections and Kaposi sarcoma (KS),
and is classified as “unmasking” when it leads to a
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new HIV-associated condition that was not evident prior to
ART, or “paradoxical” when it leads to worsening of a condition
recognized and treated prior to ART [4–11]. Clinical character-
istics and survival for lymphoma IRIS are unknown. We iden-
tified patients in a large HIV-associated lymphoma cohort
meeting a uniformly applied unmasking IRIS case definition,
and compared lymphoma IRIS and non-IRIS cases. Our data
did not allow us to distinguish paradoxical lymphoma IRIS
from refractory lymphoma due to aggressive tumor behavior
alone, and we therefore focused on unmasking lymphoma IRIS.
METHODS
Patients
The Center for AIDS Research (CFAR) Network of Integrated
Clinical Systems (CNICS) cohort includes >27 000 HIV-
infected adults 18 years and older receiving care since 1 January
1995 at 8 United States CFAR sites [12]. We examined individ-
uals with NHL or HL diagnosed between 1 January 1996 and 31
December 2011. Follow-up was administratively censored on 31
December 2011.
Procedures
CNICS captures comprehensive clinical data through electronic
health records (EHRs) and other institutional data systems at
each site. Historical information are collected upon cohort
entry. Data quality is assessed prior to transmission to
CNICS. After integration into the CNICS repository, data un-
dergo extensive quality assurance. A standardized cancer verifi-
cation procedure has been established [13], and cancer
diagnoses are reviewed to collect information regarding type,
histology, stage, and treatment. If >1 lymphoma diagnosis or re-
lapse was recorded, we analyzed the first occurrence. Patients
are enrolled in CNICS upon entering care at HIV clinics, but
data may be available from EHRs prior to enrollment. To in-
crease generalizability, we included individuals diagnosed with
lymphoma before and after CNICS entry to avoid excluding pa-
tients newly diagnosed with HIV, out of care, or transferring
HIV care at the time of lymphoma diagnosis. Mortality data
are obtained from clinic sources and the Social Security Death
Index.
Unmasking lymphoma IRIS was defined as NHL or HL diag-
nosed within 6 months after ART initiation with virologic sup-
pression, defined as ≥0.5 log reduction in HIV RNA log10
copies/mL. This was modified from existing KS IRIS definitions,
and IRIS definitions for tuberculous and cryptococcal disease
taken from the International Network for the Study of HIV-
associated IRIS [4, 5, 10, 11, 14]. For HIV RNA, the pre-ART
measurement was the closest value to ART start date within 3
months before the ART start date. Post-ART HIV RNA at lym-
phoma diagnosis was the value closest to lymphoma diagnosis,
which occurred after ART start date and up to 3 months after
lymphoma diagnosis. For non-IRIS cases, HIV RNA at lympho-
ma diagnosis was the value closest to lymphoma diagnosis be-
ginning 3 months before until 3 months after. Suppressed HIV
RNA was defined as <400 copies/mL. CD4 count at lymphoma
diagnosis was the value closest to lymphoma diagnosis begin-
ning 3 months before until 3 months after. Nadir CD4 count
was the lowest CD4 count at any time on or before the date
of CD4 count at lymphoma diagnosis. Hepatitis B coinfection
was defined as any positive hepatitis B surface antigen or
DNA result, and hepatitis C coinfection as any positive hepatitis
C antibody or RNA result, before or until 6 months after lym-
phoma diagnosis.
Statistical Analysis
Differences between IRIS and non-IRIS were assessed using χ2
or Fisher exact test, 1-way analysis of variance, and Kruskal-
Wallis test. To assess CD4 and HIV RNA during the 12 months
before and after lymphoma diagnosis, summative curves were
derived by plotting median and interquartile values at each
monthly time point across all patients within each group. Indi-
vidual patient–level CD4 and HIV RNA curves were generated
by plotting all available measurements for each patient over this
time period and imputing values in between assuming a linear
trajectory. To estimate trends over the entire 2-year period, first
available measurements within the time period were carried
backward to 12 months before lymphoma diagnosis, and last
available measurements were carried forward to 12 months
after lymphoma diagnosis. CD4 and HIV RNA values for
each patient at each monthly time point were assigned based
on the value at which individual curves intersected each month-
ly time point.
Mortality rates were calculated as number of deaths per 100
person-years of follow-up. Follow-up time was calculated from
date of lymphoma diagnosis until administrative censoring,
death, or loss to follow-up. Loss to follow-up date was based
on last date of any clinical activity in CNICS. To minimize sur-
vival bias, patients with lymphoma diagnosed before HIV clinic
attendance and CNICS enrollment were treated as late entries
who contributed follow-up time only after CNICS entry [15]. Ka-
plan-Meier curves were used to estimate overall survival after
lymphoma diagnosis, and Cox proportional hazards were used
to assess differences in survival between IRIS and non-IRIS.
We conducted sensitivity analyses varying the IRIS definition
to include (1) lymphoma within 3 months of ART accompanied
by ≥0.5 log HIV RNA reduction; (2) lymphoma within 6
months of ART accompanied by ≥1 log HIV RNA reduction;
and (3) lymphoma within 3 months of ART accompanied by
≥1 log HIV RNA reduction. We performed sensitivity analyses
restricted to patients diagnosed with lymphoma after CNICS
enrollment. All analyses were conducted using SAS version
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9.3. A 2-sided α value of .05 was used to assess statistical signifi-
cance. Patients were excluded from analyses that included var-
iables for which data were missing.
RESULTS
Of 24 203 HIV-infected individuals in CNICS, 482 (2%) indi-
viduals were diagnosed with lymphoma between 1996 and
2011. Of these, 201 (42%) were diagnosed a median 4.3 months
(interquartile range [IQR], 1.1–24.1) before CNICS enrollment.
Patients with lymphoma diagnosed before CNICS enrollment
were more likely to have any missing value for CD4 count at
lymphoma diagnosis, nadir CD4 count, or HIV RNA at lym-
phoma diagnosis compared with patients for whom lymphoma
was diagnosed after cohort entry (44% vs 12%, P < .0001). CD4
count and HIV RNA measurements at lymphoma diagnosis
differed from lymphoma diagnosis date by a median of 12
days (IQR, 4–27) and 13 days (IQR, 4–29), respectively.
Fifty-six of 482 patients (12%) met the unmasking lymphoma
IRIS case definition. Among non-IRIS cases, 9 patients were di-
agnosed with lymphoma within 6 months after ART, but without
documented HIV RNA reduction as required by the unmasking
IRIS case definition. Baseline characteristics for IRIS and non-
IRIS cases are shown in Table 1. Among IRIS cases, 12 (21%)
had HL, 22 (39%) diffuse large B-cell lymphoma (DLBCL), 5
(9%) Burkitt lymphoma (BL), 10 (18%) primary central nervous
system lymphoma (PCNSL), and 7 (13%) other NHL. Median
CD4 count at lymphoma diagnosis among IRIS cases was 173
cells/mL (IQR, 73–302), and 48% had HIV RNA <400 copies/
mL. No significant differences were identified between IRIS
and non-IRIS, excepting more frequent hepatitis B and C (30%
vs 19%, P = .05), more frequent prior AIDS (91% vs 79%,
P = .03), lower HIV RNA (2.7 vs 4.5 log10 copies/mL, P <
.0001), and higher proportion with suppressed HIV RNA (48%
vs 30%, P = .0009) among IRIS cases. HIV RNA differences re-
sulted in part from the IRIS case definition, which required viro-
logic response to ART. No significant differences in lymphoma
subtype distribution were identified between IRIS and non-IRIS
cases, although numerically higher proportions of HL (21% vs
16%, P = .30) and PCNSL (18% vs 10%, P = .09) were observed
among IRIS. Unmasking lymphoma IRIS cases were on ART
for a median 2.2 months (IQR, 0.9–3.5) before lymphoma diag-
nosis. Among 426 non-IRIS cases, 175 (41%) were on ART at
lymphoma diagnosis for a median 20.3 months (IQR, 7.5–
42.9), of whom 83 of 142 (58%) with an HIV RNAvalue recorded
at lymphoma diagnosis had suppressed HIV RNA. Differences in
ART duration between IRIS and non-IRIS cases were influenced
by the IRIS case definition, which required lymphoma diagnosis
within 6 months after ART initiation.
Median CD4 count and HIV RNA with interquartile ranges
during the 12 months before and after lymphoma diagnosis are
shown in Figure 1 for IRIS, non-IRIS on ART, and non-IRIS off
ART at lymphoma diagnosis. During the 24-month window,
Table 1. Characteristics of 482 HIV-Infected Adults in the Center
for AIDS Research Network of Integrated Clinical Systems Cohort
With Lymphoma Between 1996 and 2011, Stratified by Unmasking








41.1 (7.0) 42.5 (9.0) .19
Male, No. (%) 51 (91.1) 375 (88.0) .66
Race/ethnicitya, No. (%)
White 28 (50.0) 211 (50.1) .99
Black 21 (37.5) 134 (31.8) .39








Lymphoma category, No. (%)
HL 12 (21.4) 68 (16.0) .30
DLBCL 22 (39.3) 183 (43.0) .66
BL 5 (8.9) 52 (12.2) .60
PCNSL 10 (17.9) 44 (10.3) .09
Other NHL 7 (12.5) 79 (18.5) .27
Lymphoma stage I/II, No.
(%)a
9 (39.1) 38 (24.2) .13
Hepatitis B/C coinfection 17 (30.4) 81 (19.0) .047
AIDS illness prior to
lymphoma diagnosis,
No. (%)
51 (91.1) 337 (79.1) .032
On ART at lymphoma
diagnosis, No. (%)
56 (100.0) 175 (41.1) <.0001
CD4 count at lymphoma
diagnosis, cells/µL,
median (IQR)a




14.0 (6.8–21.0) 12.0 (5.3–22.0) .34
CD4 count nadir, cells/µL,
median (IQR)a
69 (29–177) 58 (15–167) .54




2.72 (1.48–3.98) 4.52 (2.30–5.30) <.0001
HIV RNA <400 copies/
mL at lymphoma
diagnosis, No. (%)a
27 (48.2) 93 (30.3) .0009
Abbreviations: ART, antiretroviral therapy; BL, Burkitt lymphoma; DLBCL,
diffuse large B-cell lymphoma; HIV, human immunodeficiency virus; HL,
Hodgkin lymphoma; IQR, interquartile range; IRIS, immune reconstitution
inflammatory syndrome; NHL, non-Hodgkin lymphoma; PCNSL, primary
central nervous system lymphoma; SD, standard deviation.
a No. (%) of missing observations, IRIS/non-IRIS: race/ethnicity = 0 (0%)/5
(1.2%); lymphoma stage = 33 (58.9%)/269 (63.1%); CD4 count at lymphoma
diagnosis = 0 (0%)/97 (22.8%); CD4 percentage at lymphoma diagnosis = 1
(1.8%)/122 (28.6%); CD4 count nadir = 0 (0.0%)/67 (15.7%); HIV RNA at
lymphoma diagnosis = 0 (0.0%)/119 (27.9%).
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Figure 1. Median CD4, human immunodeficiency virus (HIV) RNA, and interquartile ranges for 482 HIV-infected adults in Centers for AIDS Research
Network of Integrated Clinical Systems during the 12 months before and after lymphoma diagnosis, stratified by immune reconstitution inflammatory syn-
drome (IRIS) and antiretroviral therapy (ART) status. Solid lines indicate median values and dashed lines interquartile ranges.
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there were 3439 CD4 count measures for the study population,
with a median of 8 (IQR, 5–10) per patient (IRIS, 10 [IQR, 8–
12]; non-IRIS on ART, 6 [IQR, 5–9]; and non-IRIS off ART, 8
[IQR, 6–11]). During the 24-month window, there were 3266
HIV RNA measures for the study population, with a median
of 7 (IQR, 5–10) per patient (IRIS, 9 [IQR, 8–11]; non-IRIS
on ART, 6 [IQR 4–8]; and non-IRIS off ART, 8 [IQR, 6–11]).
IRIS cases demonstrated marked reductions in HIV RNA
after ART in the months before lymphoma diagnosis without
significant CD4 increases, perhaps reflecting lymphoma-related
lymphopenia. In the 12 months after lymphoma diagnosis, IRIS
cases demonstrated modest CD4 count increases. Non-IRIS
cases on ART demonstrated modest CD4 count increases and
HIV RNA reductions after lymphoma diagnosis, perhaps from
intensified ART, greater engagement in care, and/or enhanced
adherence counseling. Non-IRIS cases off ART demonstrated
robust CD4 count increases and HIV RNA reductions after
lymphoma diagnosis, resulting fromART initiation by 6months
after lymphoma diagnosis in 198 of 251 (79%) patients.
Among all 482 patients, 229 deaths occurred during 1571
person-years of follow-up, yielding a mortality rate of 14.6
deaths per 100 person-years (95% confidence interval [CI],
12.8–16.6; Table 2). Five-year survival was 44% for all lympho-
ma, 61% for HL, 51% for BL, 44% for DLBCL, 44% for other
NHL, and 23% for PCNSL. Although not statistically signifi-
cant, overall survival appeared worse at 6 months for IRIS
than for non-IRIS cases (62% IRIS [95% CI, 50%–76%] vs
72% non-IRIS [95% CI, 67%–77%]), and also 1 year after lym-
phoma diagnosis (54% IRIS [95% CI, 42%–69%] vs 61%
non-IRIS [56%–67%]). However, overall survival 5 years after
lymphoma diagnosis was similar (49% IRIS [95% CI, 37%–
64%] vs 44% non-IRIS [95% CI, 39%–50%]) (Figure 2).
When follow-up time was partitioned at 6-month and 1-year
time points, a pattern of increased early mortality followed by
reduced late mortality was suggested for IRIS (hazard ratios
[HRs], 1.42 [95% CI, .88–2.30] for 0–6 months; 0.62 [95% CI,
.27–1.41] for 6 months–5 years; 1.28 [95% CI, .83–1.97] for 0–1
year; and 0.32 [95% CI, .08–1.31] for 1–5 years). This pattern of
similar long-term survival but possibly increased early mortal-
ity was also observed when IRIS were separately compared with
non-IRIS cases on ART at lymphoma diagnosis, and also to
non-IRIS cases off ART. Despite limitations from small numbers
Table 2. Mortality Rates and Survival for 482 HIV-Infected Adults in the Center for AIDS Research Network of Integrated Clinical Systems
Cohort With Lymphoma Between 1996 and 2011, Stratified by Histology and Unmasking Immune Reconstitution Inflammatory Syndrome
Case Status










All lymphoma 482 229 1571 14.6 (12.8–16.6) 70 (66–75) 60 (55–65) 44 (40–50)
IRIS 56 30 169 17.7 (12.4–23.4) 62 (50–76) 54 (42–69) 49 (37–64)
Non-IRIS 426 199 1402 14.2 (12.4–16.3) 72 (67–77) 61 (56–67) 44 (39–50)
HL 80 25 302 8.3 (5.6–12.2) 82 (73–92) 77 (67–88) 61 (50–75)
IRIS 12 2 52 3.9 (1.0–15.4) 82 (71–93) 83 (65–100) 83 (65–100)
Non-IRIS 68 23 250 9.2 (6.1–13.8) 82 (73–93) 76 (65–89) 57 (45–73)
All NHL 402 204 1269 16.1 (14.0–18.4) 68 (63–73) 57 (51–62) 41 (36–47)
IRIS 44 28 118 23.9 (16.5–34.6) 56 (43–73) 46 (34–64) 40 (27–58)
Non-IRIS 358 176 1152 15.3 (13.2–17.7) 70 (64–76) 58 (53–65) 42 (36–48)
BL 57 23 157 14.6 (9.7–22.0) 73 (61–88) 63 (50–79) 51 (38–68)
IRIS 5 3 5 62.7 (20.2–194.5) 60 (32–100) 40 (16–99) 40 (16–99)
Non-IRIS 52 20 153 13.1 (8.5–20.3) 75 (62–90) 66 (53–82) 53 (39–71)
PCNSL 54 41 121 33.8 (24.9–45.9) 38 (27–54) 28 (18–43) 23 (14–37)
IRIS 10 10 2 417.6 (224.7–776.2) 10 (2–4) 0 (0–0) 0 (0–0)
Non-IRIS 44 31 119 26.1 (18.3–37.1) 45 (32–63) 34 (23–51) 28 (18–44)
DLBCL 205 101 692 14.6 (12.0–17.7) 75 (69–83) 64 (57–72) 44 (37–53)
IRIS 22 10 85 11.8 (6.3–21.9) 72 (55–93) 67 (50–90) 54 (36–81)
Non-IRIS 183 91 608 15.0 (12.2–18.4) 76 (69–84) 64 (56–72) 43 (36–52)
Other NHL 86 39 298 13.1 (9.6–17.9) 71 (60–84) 59 (47–73) 44 (33–59)
IRIS 7 5 24 19.7 (8.2–47.4) 71 (46–100) 57 (32–100) 57 (32–100)
Non-IRIS 79 34 273 12.5 (8.9–17.5) 71(59–86) 60 (47–75) 43 (32–58)
Abbreviations: BL, Burkitt lymphoma; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; HIV, human immunodeficiency virus; HL, Hodgkin lymphoma;
IRIS, immune reconstitution inflammatory syndrome; NHL, non-Hodgkin lymphoma; PCNSL, primary central nervous system lymphoma.
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of IRIS cases within histologic groups, possibly increased early
mortality for IRIS was most strongly suggested for NHL, partic-
ularly BL and PCNSL.
Sensitivity analyses varying the IRIS case definition were con-
ducted as follows: (1) lymphoma within 3 months of ART with
≥0.5 log HIV RNA reduction (n = 33); (2) lymphoma within 6
months of ART with ≥1 log HIV RNA reduction (n = 41); and
(3) lymphoma within 3 months of ART with ≥1 log HIV RNA
reduction (n = 23). In these analyses, IRIS and non-IRIS were
similar overall, with consistent demonstration of more frequent
hepatitis B and C and lower HIV RNA at lymphoma diagnosis
among IRIS cases, and consistently higher PCNSL proportions
reaching statistical significance using IRIS case definitions (1)
and (2). Similar overall survival between IRIS and non-IRIS
cases 5 years after lymphoma diagnosis was also observed across
varying IRIS case definitions, with possibly increased early mor-
tality for IRIS consistently demonstrated. When analyses were
restricted to 281 patients with lymphoma diagnosed after
CNICS enrollment, 56 (20%) were classified as IRIS and 225
as non-IRIS, with findings otherwise similar.
DISCUSSION
In a multicenter HIV-associated lymphoma cohort, 12% of
patients met a uniformly applied unmasking IRIS case defini-
tion. These results are descriptive, but important given that
lymphoma IRIS has not been characterized in detail. Our find-
ings support the concept of lymphoma IRIS as a distinct and
definable entity, and extend previous cohort studies demon-
strating increased lymphoma incidence during the first
6 months after ART [1–3].
Lymphomagenesis in HIV-infected individuals is complex,
involving viral oncogens such as Epstein-Barr virus (EBV),
immune surveillance in the germinal center, tumor microenvi-
ronment interactions, activation of cell signaling pathways such
as nuclear factor–κB, and chronic B-cell activation, all of which
vary in relative contribution across histologic subtypes [16–23].
Although no significant differences were observed in histologic
distribution between lymphoma IRIS and non-IRIS, there was
a suggestion of increased HL and PCNSL among IRIS cases.
This should be interpreted with caution given small numbers
of IRIS cases. However, HL and PCNSL are the HIV-associated
lymphoma subtypes for which EBV is most consistently demon-
strated in tumor specimens [16]. Examining EBV status among
lymphoma IRIS patients may be informative, particularly since
other herpesviruses, including KS-associated herpesvirus, cyto-
megalovirus, herpes simplex virus, and varicella zoster virus,
are commonly implicated in IRIS presentations [6–8]. Possibly
increased hepatitis B/C coinfection among IRIS cases may also
be notable. Unlike EBV, which directly infects and transforms
lymphocytes, hepatitis B and C increase NHL risk by inducing
chronic immune activation and B-cell stimulation [24]. HIV-
associated lymphomas, in which immune activation plays a path-
ogenically stronger role, may be more susceptible to IRIS effects.
Our results are consistent with the IRIS literature. First, 12%
of HIV-associated lymphoma patients met an unmasking lym-
phoma IRIS case definition. IRIS is common after ART, occur-
ring in 5%–15% of ART initiators with increased risk among
those with advanced immunosuppression [6–8, 11, 14]. HIV-
infected lymphoma patients present with advanced immuno-
suppression even in the ART era [25]. Identifying unmasking
IRIS in a significant number of patients from a large HIV-
associated lymphoma cohort may therefore not be surprising.
Unmasking lymphoma IRIS cases were on ART for a median
2.2 months prior to lymphoma diagnosis, consistent with
peak IRIS incidence within the first 3 months on ART [6, 7].
We also observed possibly increased early mortality among
lymphoma IRIS cases, but similar long-term outcomes to
non-IRIS, as with previous IRIS descriptions [6, 7]. This pattern
was particularly observed for NHL. Notably, PCNSL IRIS cases
had much worse outcomes than non-IRIS cases. Increased mor-
tality has been described for other forms of IRIS involving the
CNS, as excess intracranial inflammation leads to significant
morbidity and mortality [6, 8, 26–28]. BL IRIS also appeared
to have worse survival than non-IRIS, perhaps reflecting IRIS
in a highly proliferative lymphoma subtype with frequent extra-
nodal and CNS involvement [16, 29, 30].
Figure 2. Overall survival for 482 HIV-infected adults in Centers for AIDS
Research Network of Integrated Clinical Systems (CNICS) with lymphoma
between 1996 and 2011, stratified by unmasking immune reconstitution
inflammatory syndrome (IRIS) case status. Patients enrolled in CNICS
after lymphoma diagnosis were treated as late entries. Abbreviation:
HIV, human immunodeficiency virus.
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Detailed lymphoma IRIS studies may elucidate immunologic
mechanisms of lymphoma control. Treating human cancer by
stimulating tumor-specific T lymphocytes is a promising ther-
apeutic strategy. Immune activating cancer therapies include
inhibitors of programmed death 1 (PD-1) and cytotoxic
T-lymphocyte-associated antigen 4 (CTLA-4) signaling [31,
32]. Activation of the PD-1 pathway is found in aggressive
B-cell lymphomas, as well as virus- and immunodeficiency-
associated malignancies [33]. Some immune-based cancer treat-
ments are characterized by immunologic toxicities that may
require systemic corticosteroids and immunomodulatory thera-
pies not unlike severe IRIS, but a substantial rate of durable can-
cer remissions [34–36]. HIV-associated IRIS is characterized by
a rapid increase in CD4 cells, lymphocyte proliferation respons-
es, immune activation, and pathogen-specific delayed hypersen-
sitivity [37–40]. Despite small numbers, we observed possibly
increased early mortality followed by reduced late mortality
among IRIS cases, with near plateauing of survival after
1 year. The similarity of this observation to findings from clin-
ical trials of immune-based cancer treatments suggest that more
detailed studies of lymphoma IRIS might yield immunobiologic
insights with relevance even for HIV-uninfected patients.
Our research has several limitations. First, existing IRIS case
definitions are not standardized. We applied a uniform case def-
inition drawn from the literature, and varied this in sensitivity
analyses yielding consistent results. Second, subclinical lympho-
ma leading to care-seeking behavior and ART initiation before
lymphoma diagnosis could not be excluded. Third, data did not
allow for a distinction between refractory lymphoma and para-
doxical lymphoma IRIS, in which ART after lymphoma diagno-
sis may have led to clinical worsening. Paradoxical lymphoma
IRIS would have been classified as non-IRIS, perhaps mitigating
differences between groups. Fourth, data are observational and
unadjusted, and associations may be due to measured and un-
measured confounding. Given small numbers of IRIS cases
within histologic groups, we did not adjust for other covariates,
although measured covariates were similar overall between IRIS
and non-IRIS. Fifth, CNICS enrollment requires HIV clinic at-
tendance, and patients with lymphoma diagnosis preceding
CNICS enrollment are included, for whom data may have
been incomplete. We sought to maintain generalizability to pa-
tients not receiving HIV care or newly diagnosed with HIV at
lymphoma diagnosis. We minimized bias by analyzing follow-
up time only after CNICS entry and sought to ensure that “im-
mortal” person-time between lymphoma diagnosis and cohort
entry was not inappropriately counted. We restricted analyses to
patients with lymphoma diagnosis after CNICS enrollment and
found consistent results. However, survival for patients with
lymphoma before CNICS enrollment may not be accurately
reflected. Sixth, detailed information regarding lymphoma pre-
sentation and treatment were not analyzed. We are implement-
ing a centralized abstraction to collect these data. Finally, cause
of death was unknown, and analyses focused on overall survival.
Despite limitations, our study has several strengths. To our
knowledge, this is thefirst detailed description ofHIV-associated
lymphoma IRIS using a uniformly applied case definition. Al-
though we identified only 56 cases of unmasking lymphoma
IRIS, results are drawn from one of the largest multicenter
HIV-associated lymphoma cohorts to date, providing a dataset
from which characterizing a rare clinical entity like lymphoma
IRIS is even possible. Patients studied represent a large and di-
verse HIV-infected population in routine care across the United
States, undergoing regular assessment, in whom lymphoma di-
agnoses were extensively verified. Additionally, mortality assess-
ment used active and passive surveillance.
In conclusion, 12% of HIV-associated lymphoma patients
from a large multicenter cohort met a uniformly applied case
definition for unmasking lymphoma IRIS. These patients
were similar overall to non-IRIS cases, with similarities also to
nonlymphoma IRIS descriptions. Five-year survival was com-
parable between IRIS and non-IRIS cases, although increased
early mortality among IRIS cases was suggested. Detailed stud-
ies of lymphoma IRIS immunobiology may have implications
for HIV-infected and HIV-uninfected individuals.
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